Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
TPST Tempest Therapeutics	$6.67 -2.6%	$8.86	$5.35 ▼ $48.93	$24.38M	-1.78	158,609 shs	32,121 shs
VTYX Ventyx Biosciences	$1.21 -12.3%	$1.24	$0.78 ▼ $5.66	$86.11M	0.73	1.28 million shs	1.45 million shs
ZNTL Zentalis Pharmaceuticals	$1.25 -8.1%	$1.54	$1.01 ▼ $13.24	$89.94M	1.81	1.55 million shs	786,510 shs
ZURA Zura Bio	$1.22 -15.3%	$1.28	$0.97 ▼ $6.35	$83.42M	0.05	389,243 shs	543,377 shs

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
TPST Tempest Therapeutics	-2.00%	-12.52%	-14.20%	-43.29%	-85.72%
VTYX Ventyx Biosciences	-4.83%	+11.29%	+46.84%	-25.00%	-71.55%
ZNTL Zentalis Pharmaceuticals	-6.21%	-4.23%	+16.24%	-16.56%	-88.39%
ZURA Zura Bio	-2.04%	+2.13%	+39.81%	-15.79%	-68.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
TPST Tempest Therapeutics	1.7027 of 5 stars	3.3	5.0	0.0	0.0	0.6
VTYX Ventyx Biosciences	2.3941 of 5 stars	3.4	2.0	2.7	2.5	0.6
ZNTL Zentalis Pharmaceuticals	2.0171 of 5 stars	3.2	2.0	2.6	1.7	0.6
ZURA Zura Bio	3.1888 of 5 stars	3.6	3.0	3.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
TPST Tempest Therapeutics	2.50	Moderate Buy	$30.00	349.78% Upside
VTYX Ventyx Biosciences	2.75	Moderate Buy	$10.00	726.45% Upside
ZNTL Zentalis Pharmaceuticals	2.44	Hold	$8.24	559.56% Upside
ZURA Zura Bio	3.13	Buy	$14.67	1,102.19% Upside

Current Analyst Ratings Breakdown

Latest TPST, ZURA, VTYX, and ZNTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2025	TPST Tempest Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$16.00 ➝ $16.00
4/10/2025	TPST Tempest Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Perform	$7.00 ➝ $9.00
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
3/28/2025	TPST Tempest Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$169.00 ➝ $91.00
3/28/2025	TPST Tempest Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$611.00 ➝ $208.00
3/28/2025	ZNTL Zentalis Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00
3/27/2025	ZNTL Zentalis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/26/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $19.00
3/26/2025	ZURA Zura Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/26/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00

(Data available from 5/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	$1.39 per share	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	$4.13 per share	N/A
ZNTL Zentalis Pharmaceuticals	$67.43M	1.33	N/A	N/A	$6.18 per share	0.20
ZURA Zura Bio	N/A	N/A	N/A	N/A	$1.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
TPST Tempest Therapeutics	-$29.49M	-$19.51	N/A	N/A	N/A	N/A	-187.44%	-82.61%	5/8/2025 (Estimated)
VTYX Ventyx Biosciences	-$192.96M	-$1.98	N/A	N/A	N/A	N/A	-54.94%	-50.01%	5/8/2025 (Estimated)
ZNTL Zentalis Pharmaceuticals	-$292.19M	-$2.32	N/A	N/A	N/A	N/A	-43.91%	-34.96%	5/6/2025 (Estimated)
ZURA Zura Bio	-$69.24M	-$0.53	N/A	N/A	N/A	N/A	-37.36%	-29.81%	5/8/2025 (Estimated)

Latest TPST, ZURA, VTYX, and ZNTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	TPST Tempest Therapeutics	-$0.31	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	VTYX Ventyx Biosciences	-$0.48	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	ZURA Zura Bio	-$0.17	N/A	N/A	N/A	N/A	N/A
5/6/2025	Q1 2025	ZNTL Zentalis Pharmaceuticals	-$0.70	N/A	N/A	N/A	N/A	N/A
3/27/2025	Q4 2024	TPST Tempest Therapeutics	-$3.12	-$4.03	-$0.91	-$0.31	N/A	$0.49 million
3/26/2025	Q4 2024	ZNTL Zentalis Pharmaceuticals	-$0.75	-$0.66	+$0.09	-$0.66	N/A	$26.90 million
3/25/2025	Q4 2024	ZURA Zura Bio	-$0.17	-$0.08	+$0.09	-$0.08	N/A	$0.00 million
2/27/2025	Q4 2024	VTYX Ventyx Biosciences	-$0.54	-$0.41	+$0.13	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
TPST Tempest Therapeutics	N/A	1.69	1.69
VTYX Ventyx Biosciences	N/A	23.52	23.52
ZNTL Zentalis Pharmaceuticals	N/A	7.29	7.29
ZURA Zura Bio	N/A	10.36	10.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
TPST Tempest Therapeutics	22.52%
VTYX Ventyx Biosciences	97.88%
ZNTL Zentalis Pharmaceuticals	N/A
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
TPST Tempest Therapeutics	4.70%
VTYX Ventyx Biosciences	18.18%
ZNTL Zentalis Pharmaceuticals	3.60%
ZURA Zura Bio	22.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
TPST Tempest Therapeutics	20	3.66 million	41.59 million	Optionable
VTYX Ventyx Biosciences	30	71.16 million	57.86 million	Optionable
ZNTL Zentalis Pharmaceuticals	160	71.95 million	68.70 million	Optionable
ZURA Zura Bio	3	68.38 million	50.86 million	Optionable

TPST, ZURA, VTYX, and ZNTL Headlines

Recent News About These Companies

Boxer Capital Management LLC Makes New Investment in Zura Bio Limited (NASDAQ:ZURA)

May 4 at 6:25 AM | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Receives $14.67 Consensus PT from Brokerages

May 4 at 1:57 AM | americanbankingnews.com

Zura Bio (ZURA) Projected to Post Quarterly Earnings on Thursday

May 3 at 5:31 AM | marketbeat.com

Adage Capital Partners GP L.L.C. Buys Shares of 300,000 Zura Bio Limited (NASDAQ:ZURA)

May 2, 2025 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of "Buy" from Analysts

May 1, 2025 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Short Interest Down 51.8% in April

April 30, 2025 | marketbeat.com

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

JPMorgan Chase & Co. Raises Stock Holdings in Zura Bio Limited (NASDAQ:ZURA)

April 20, 2025 | marketbeat.com

ADAR1 Capital Management LLC Cuts Stake in Zura Bio Limited (NASDAQ:ZURA)

April 9, 2025 | marketbeat.com

HC Wainwright Has Negative Estimate for Zura Bio Q1 Earnings

April 8, 2025 | marketbeat.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 26, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025 | businesswire.com

ZURA stock touches 52-week low at $1.44 amid market shifts

February 11, 2025 | msn.com

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)

January 24, 2025 | zacks.com

We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth

January 22, 2025 | finance.yahoo.com

Zura Bio Highlights Strategic Goals and Clinical Advances

January 13, 2025 | tipranks.com

Zura Bio initiates Phase II systemic sclerosis treatment trial

December 25, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST, ZURA, VTYX, and ZNTL Company Descriptions

Tempest Therapeutics NASDAQ:TPST

$6.67 -0.18 (-2.63%)

Closing price 04:00 PM Eastern

Extended Trading

$6.67 0.00 (0.00%)

As of 07:47 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Ventyx Biosciences NASDAQ:VTYX

$1.21 -0.17 (-12.32%)

Closing price 04:00 PM Eastern

Extended Trading

$1.22 +0.01 (+0.83%)

As of 07:44 PM Eastern

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$1.25 -0.11 (-8.09%)

Closing price 04:00 PM Eastern

Extended Trading

$1.28 +0.03 (+2.40%)

As of 07:53 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Zura Bio NASDAQ:ZURA

$1.22 -0.22 (-15.28%)

Closing price 04:00 PM Eastern

Extended Trading

$1.17 -0.05 (-4.02%)

As of 07:53 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time